| Patient | Marie Curie |
|---|---|
| Date of birth | 1867-11-07 |
| Identifiers | MRN HR-ET013-SYN-TD; SSN (made up) 000-13-2758 |
| Document date | 1934-06-29 |
| Author | Adaeze Nwosu, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review on immunosuppressive therapy, one week after laser capsulotomy. [S]
Madame Curie returns six weeks after starting immunosuppressive therapy. She has had no fever, infection, or bleeding, and the bruising has lessened. She has a little more energy in the afternoons. She takes cyclosporine, eltrombopag, and acyclovir as prescribed. Ophthalmology confirmed posterior capsule opacification in the right eye two weeks ago and performed a YAG laser capsulotomy one week ago. She now reads standard print without glare, with no eye pain, redness, new floaters, flashes, or shadow in her vision. She is frustrated at being away from her laboratory. [S]
| Element | Detail |
|---|---|
| Infection and bleeding | None; fewer bruises |
| Energy | A little better in the afternoons |
| Adherence | Cyclosporine, eltrombopag, and acyclovir as prescribed |
| Eye | Laser capsulotomy one week ago; reading standard print without glare |
| After laser | No pain, redness, new floaters, flashes, or shadow |
| Mood | Frustrated at time away from the laboratory |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue improving; no fever |
| Hematologic | Negative | No new bruising or bleeding |
| Eyes | Negative | Clear reading vision on the right; no pain, floaters, flashes, or shadow |
| Skin | Negative | No rash |
| Psychiatric | Positive | Frustrated at time away from work; sleeping and eating well; PHQ-2 score 2 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology | One capsule by mouth twice daily; hematology adjusts the dose to trough levels | Oral route | 1934-05-18 | active | S |
| Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach | Two tablets by mouth once daily, two hours before or four hours after food, dairy, or antacids | Oral route | 1934-05-18 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression | One tablet by mouth twice daily | Oral route | 1934-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1934-06-29 | Body height | 157 | cm | S |
| 1934-06-29 | Body weight | 52 | kg | S |
| 1934-06-29 | Body mass index (BMI) [Ratio] | 21.1 | kg/m2 | S |
| 1934-06-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1934-06-29 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1934-06-29 | Heart rate | 86 | /min | S |
| 1934-06-29 | Respiratory rate | 16 | /min | S |
| 1934-06-29 | Body temperature | 36.7 | Cel | S |
| 1934-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1934-06-29 | Hemoglobin [Mass/volume] in Blood | 8.9 | g/dL | 11.6-15 g/dL | Low | S |
| 1934-06-29 | Leukocytes [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1934-06-29 | Neutrophils [#/volume] in Blood by Automated count | 0.8 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1934-06-29 | Platelets [#/volume] in Blood by Automated count | 34 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1934-06-29 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 | fL | 80-100 fL | High | S |
| 1934-06-29 | Reticulocytes [#/volume] in Blood by Automated count | 31 | 10*3/uL | 25-100 10*3/uL | Normal | S |
| 1934-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 1934-06-29 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1934-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1934-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1934-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1929)/1.73 sq M | 61 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1934-06-29 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 1934-06-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 1934-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Less pale; alert and engaged |
| Mouth | No ulcers, thrush, or gum swelling |
| Skin | Fading bruises on the shins; no petechiae |
| Heart | Regular rhythm, pulse 86 |
| Eyes | Right red reflex now clear; both eyes white and quiet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe aplastic anemia: pancytopenia with a low reticulocyte count, confirmed by a hypocellular bone marrow; attributed to cumulative occupational ionizing radiation; linked to the documented 1842 diagnosis | active | confirmed | D61.2 | S — Synthetic modern diagnosis; the 1934 report remains D and the radiation cause is R. |
| Occupational exposure to ionizing radiation over decades of radium research and X-ray work | active | confirmed | Z57.1 | S — Synthetic modern coding of the documented exposure history. |
| Posterior capsule opacification, right eye, after earlier bilateral cataract surgery; glare and blurred reading vision | active | confirmed | H26.491 | S — Synthetic eye finding linked to the documented cataracts and operations. |
| Chronic radiodermatitis of the fingertips, with thin, scarred skin | active | confirmed | L58.1 | S — Synthetic skin finding linked to the documented finger burns. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CBC with differential and reticulocyte count | Weekly during the first months of treatment | Completed today | Hemoglobin 8.9 g/dL, white cells 2.4, neutrophils 0.8, platelets 34, reticulocytes 31 thousand per microliter |
| Laboratory | Weekly blood counts between visits | Weekly during the first months of treatment | Deferred | Again no counts are in this record between visits, a second deviation from the protocol. Counts are rising with no bleeding or infection, so no harm resulted. Corrective action: weekly counts confirmed with the hematology day unit |
| Laboratory | Creatinine, eGFR, potassium, and ALT on cyclosporine and eltrombopag | Every two weeks during the first months of treatment | Completed today | Three weeks after the last check, a week late. Creatinine 1.02 mg/dL (about 30 percent above baseline), eGFR 61, potassium 4.9, ALT 31 |
| Laboratory | Cyclosporine trough level | Regularly from the first weeks of treatment, to guide the dose | Deferred | Still no trough level in this record, a second deviation from the protocol. The creatinine rise now warrants a dose review. Corrective action: hematology contacted today for a trough and dose review |
| Laboratory | Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV) | At diagnosis, before immunosuppression | Deferred | Still not in this record. ALT remains normal. Corrective action: hematology asked again today |
| Examination | Blood pressure and weight on cyclosporine | Every visit | Completed today | 128/78 mmHg; weight 52 kg |
| Medication safety | Antiviral prophylaxis during immunosuppression | Throughout immunosuppression | Completed today | Taking acyclovir twice daily |
| Medication safety | Antibacterial and antifungal prophylaxis while severely neutropenic | While neutrophils are below 0.5 thousand per microliter, by local policy | Not indicated | Neutrophils 0.8, above the severe-neutropenia range |
| Self-management | Same-day assessment for a temperature of 38 °C or higher; bleeding precautions; no aspirin or NSAIDs | Every visit | Completed today | No fever; plan reviewed |
| Survey | Symptom assessment (fatigue, breathlessness, exercise tolerance) | Every visit during active treatment | Completed today | Energy a little better in the afternoons |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Up to date | Done by ophthalmology two weeks ago: 20/60 right and 20/30 left before laser, normal pressure, no retinal hemorrhages |
| Examination | Pressure check after laser capsulotomy | After the laser | Deferred | No post-laser pressure reading is in this record. No pain, halos, or loss of vision, and reading has improved, so no harm is apparent. Corrective action: request the laser-day note from ophthalmology |
| Self-management | Warning signs of retinal detachment after capsulotomy | After the laser | Completed today | Reviewed: new floaters, flashes, or a shadow need a same-day call |
| Survey | Functional vision assessment (reading, driving, work) | After treatment | Completed today | Reading standard print without glare |
| Survey | Depression screen (PHQ-2) | Periodically during serious illness | Completed today | Score 2, negative; frustration at time away from work |
| Survey | Response assessment (blood counts off transfusion) | At three and six months | Due | At three months |
Goal progress:
Guideline basis: Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (2024); Cataract in the Adult Eye Preferred Practice Pattern (2021); CMID: Clinical Monitoring Intelligence Database, anemia and cataract monographs (2026)
Follow-up: Weekly blood counts with creatinine and potassium this week. Primary care review in three weeks. Formal response assessment at three months. [S]